The Experts below are selected from a list of 213 Experts worldwide ranked by ideXlab platform
Tatsuro Irimura - One of the best experts on this subject based on the ideXlab platform.
-
Basic studies on a labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy
Journal of Gastroenterology, 2002Co-Authors: Terumi Bando, Tatsuro Irimura, Naoki Muguruma, Susumu Ito, Yoko Musashi, Kumi Inayama, Yoshihiro Kusaka, Masaya Tadatsu, Seiichi Shibamura, Kazuhiro TakesakoAbstract:We developed a fluorescent dye, indocyanine green (ICG)-sulfo-OSu, which was excited by infrared rays and conjugated to various antibodies. We attempted to clarify the staining patterns of anti-Sulfomucin and anti-MUC1 antibodies in gastrointestinal cancer. We then evaluated the potential of the dye as a fluorescent label for antibodies specific to cancer, to be used as a diagnostic method for microcancer, with infrared fluorescence endoscopy. Methods. Paraffin sections of samples collected from 10 patients with esophageal cancer, 30 patients with gastric cancer, and 20 patients with colorectal cancer were immunohistologically stained using an anti-Sulfomucin antibody and an anti-MUC1 antibody, and the staining patterns were examined. If a section had a high staining intensity, it was reacted with the ICG-suflo-OSu-labeled antibody and evaluated with infrared fluorescence imaging. Results. The staining patterns with the antibodies varied depending on the organs and the histological types and depth of the cancers, but the staining was generally good and the staining on the mucosal surface of cancer tissues was retained. Good images of cancer cells could be obtained by infrared fluorescence observation using the ICG-sulfo-OSu-labeled anti-MUC1 antibody. Conclusions. The anti-MUC1 antibody stained gastrointestinal cancer cells well, and nearly specific infrared fluorescence in cancer tissues was observed using the labeled anti-MUC1 antibody. The ICG-sulfo-OSu-labeled anti-MUC1 antibody has possible usefulness for the screening of cancer via infrared fluorescence endoscopy.
-
Malignant and other properties of human colon carcinoma cells after suppression of Sulfomucin production in vitro
Clinical & Experimental Metastasis, 1999Co-Authors: Hitomi Tsuiji, Shigekazu Nakatsugawa, Takeo Ishigaki, Tatsuro IrimuraAbstract:Although the loss of Sulfomucins was known as an indicator of carcinogenesis and malignant progression of colonic epithelia, it was not known whether the loss was directly related to the malignant behavior of colon carcinoma cells. We have studied the biological properties of LS174T human colon carcinoma cells before and after suppression of Sulfomucin production. Incorporation of [^35S]-sulfate into high molecular weight mucins decreased after carcinoma cell treatment with 1.5% dimethylsulfoxide (DMSO) for 8 days. The amounts of Sulfomucin determined using a Sulfomucin-specific monoclonal antibody (mAb 91.9H), in Western blot and flowcytometric analyses, also decreased. In addition, the levels of MUC2 and MUC5B mucin gene expression measured by RT-PCR were reduced after DMSO-treatment, whereas the levels of MUC1, MUC5AC, and MUC6 mucin gene expression were not. The DMSO-treated cells were tested in vitro and in vivo for their properties. Differences were not detected in their anchorage-independent growth, anchorage-dependent growth, E-selectin-dependent cell adhesion or sensitivity to interleukin (IL)-2-activated lymphocyte cytolysis. When untreated or DMSO-treated LS174T cells were injected intrasplenically into nude mice, the treated cells lacking certain cell surface Sulfomucins formed fewer metastatic colonies in the liver. These results suggest that the loss of Sulfomucins by colonic epithelial cells during progression is not directly related to the enhanced malignant behavior.
-
Reciprocal control of colon-specific Sulfomucin and sialosyl-Tn antigen expression in human colorectal neoplasia
Virchows Archiv, 1997Co-Authors: T. Yamachika, Tatsuro Irimura, Hayao Nakanishi, Ken-ichi Inada, Kuniyoshi Kitoh, Tomoyuki Kato, Masae TatematsuAbstract:Histochemical reports claim that Sulfomucins decrease and sialylated mucins increase during colon carcinogenesis. We examined the expression of colon-specific Sulfomucins and sialosyl Tn antigen (STN) in normal small intestine, normal colorectal mucosa and colorectal tumours at different stages of progression immunohistochemically, using MAb 91.9H specific for colonic Sulfomucins and MAb TKH-2 for STN. No expression of Sulfomucins recognized by MAb 91.9H was found in normal small intestine, whereas STN staining was pronounced. The converse was the case in normal colorectal mucosa. Sulfomucins were still found in adenomas, but the amounts decreased with depth of invasion in cancers ( P
-
reciprocal control of colon specific Sulfomucin and sialosyl tn antigen expression in human colorectal neoplasia
Virchows Archiv, 1997Co-Authors: T. Yamachika, Tatsuro Irimura, Hayao Nakanishi, Ken-ichi Inada, Kuniyoshi Kitoh, Tomoyuki Kato, Masae TatematsuAbstract:Histochemical reports claim that Sulfomucins decrease and sialylated mucins increase during colon carcinogenesis. We examined the expression of colon-specific Sulfomucins and sialosyl Tn antigen (STN) in normal small intestine, normal colorectal mucosa and colorectal tumours at different stages of progression immunohistochemically, using MAb 91.9H specific for colonic Sulfomucins and MAb TKH-2 for STN. No expression of Sulfomucins recognized by MAb 91.9H was found in normal small intestine, whereas STN staining was pronounced. The converse was the case in normal colorectal mucosa. Sulfomucins were still found in adenomas, but the amounts decreased with depth of invasion in cancers (P<0.001). In contrast, no STN could be detected in benign lesions, but staining became increasingly evident with invasion (P<0.001). This reciprocal control of expression of colon-specific Sulfomucins and STN evident in tumour progression indicates that the mucous phenotype shifts from the colonic to the small intestinal type.
-
Expression of Sulfomucins in Normal Mucosae, Colorectal Adenocarcinomas, and Metastases
Japanese journal of cancer research : Gann, 1995Co-Authors: Yoshifumi Matsushita, Tatsuro Irimura, Takao Yamori, Noriko Yamamoto, Hiroshi Shirahama, Sadao Tanaka, Suguru Yonezawa, Eiichi SatoAbstract:We have examined the expression of specific mucin antigens in tissue sections from 92 cases of colorectal carcinoma, using Sulfomucin-specific monoclonal antibody (MAb) 91.9H. The expression of Sulfomucins was high in normal mucosae and much lower in primary colorectal carcinoma, in metastatic lesions in lymph nodes or in liver. The intracellular localization of Sulfomucins was also different among these tissues. In normal mucosae, MAb 91.9H binding was seen in the supranuclear area, presumably Golgi complexes, the luminal surface, and secretory products. In primary colorectal carcinomas and in their metastatic lesions, MAb 91.9H was preferentially localized in the cell surface and substances attached to the luminal surface of glandular structures. Analysis of the lysates of normal and tumor tissues showed that very-high-molecular-weight components contained the antigenic epitopes. The intensity of MAb 91.9H binding was lower in tumors at advanced stages than in tumors at early stages. These high-molecular-weight components were apparently reactive with MAb FH6 specific for sialyl-Le X (s-Le X ) structures. Histological specimens with low levels of MAb 91.9H reactivity often exhibited relatively high levels of MAb FH6 reactivity. These two mucins may have reversed expression during carcinogenesis and carcinoma progression, and this change may be related to metastatic potential.
Bronislaw L. Slomiany - One of the best experts on this subject based on the ideXlab platform.
-
Association of salivary bacterial aggregating activity with Sulfomucin.
Biochemistry and molecular biology international, 1994Co-Authors: J. Piotrowski, Yotsumoto F, Amalia Slomiany, V. L.n. Murty, Czajkowski A, J. Majka, Bronislaw L. SlomianyAbstract:The requirements of human salivary mucins for aggregating potential towards the common cariogenic oral bacteria, S. mutans and S. sanguis, were investigated. Agglutination inhibition assays demonstrated that the aggregating capacity towards bacteria resides in the acidic mucin fraction. The inhibitory activity of the acidic mucin decreased only 2-4-fold following removal of sialic acid, whereas the desulfation caused a complete loss of the inhibitory potential against both bacteria. Furthermore, the aggregating capacity of mucin-derived sulfated oligosaccharide was found to be 16-fold higher than that of the sialic acid containing oligosaccharide. The results point towards the importance of salivary Sulfomucins as a predominant factor in the defense of oral cavity against cariogenic bacteria.
-
Inhibition of Helicobacter pylori colonization by an antiulcer agent, sulglycotide.
Biochemistry and molecular biology international, 1993Co-Authors: A. Czajkowski, J. Piotrowski, Yotsumoto F, Amalia Slomiany, Bronislaw L. SlomianyAbstract:Sulglycotide, a potent antiulcer agent derived from duodenal mucus glycopeptide through sulfation of the carbohydrate moieties, was evaluated with respect to its ability to interfere with H. pylori mucosal attachment. H. pylori cells were incubated with sulglycotide or human gastric mucin and then examined for their inhibitory capacity of H. pylori attachment to erythrocytes. Titration data revealed that the mucin inhibitory activity was confined to its Sulfomucin fraction, the titer of which was found to be 16-fold higher than that of intact mucin. The data with sulglycotide showed that the inhibitory titer of this agent against H. pylori attachment was at least 30-fold higher than that of the sulfated gastric mucin fraction. The results point towards the involvement of Sulfomucins in the protection of gastric mucosa from H. pylori colonization and demonstrate that sulglycotide, because of structural similarities, is ideally suited to augment the inherent mucosal defenses against this pathogen.
-
Nitecapone effect on the synthesis and secretion of gastric Sulfomucin
General pharmacology, 1993Co-Authors: Bronislaw L. Slomiany, Y.h. Liau, Amalia SlomianyAbstract:Abstract 1. 1. The effect of a new antiulcer agent, nitecapone, on the synthesis and secretion of Sulfomucin in gastric mucosa was investigated using mucosal segments incubated in the presence of [3H]proline, [3H]glucosamine and [35S]sulfate. 2. 2. The drug, while showing no discernible effect on the apomucin synthesis, evoked a dose-dependent increase in mucin glycosylation and sulfation, which at 225 μM nitecapone, attained its maximum of 1.8 and 2.2-fold stimulation, respectively. 3. 3. The analysis of mucin secretory responses revealed that nitecapone caused a concentration-dependent enhancement in Sulfomucin secretion attaining maximum increase of 1.5-fold at 150 μM nitecapone. 4. 4. The stimulatory effect of nitecapone on Sulfomucin secretion was accompanied by 1.4-fold increase in mucosal cAMP level, and showed sensitivity to protein kinase A inhibitors, thus pointing towards the involvement of protein kinase A in mediation of gastric Sulfomucin secretory responses to nitecapone. 5. 5. The ability of nitecapone to enhance Sulfomucin synthesis and secretion could be of importance to the gastroprotective action of this agent.
-
EFFECT OF EBROTIDINE ON THE SYNTHESIS AND SECRETION OF GASTRIC Sulfomucin
General pharmacology, 1993Co-Authors: Bronislaw L. Slomiany, Y.h. Liau, Amalia SlomianyAbstract:Abstract 1. 1. The effect of a new antiulcer agent, ebrotidine, on the synthesis and secretion of Sulfomucin in gastric mucosa was investigated. Rat gastric mucosal segments were incubated in DMEM containing [ 3 H]proline, [ 3 H]glucosamine and [ 35 S]Na 2 SO 4 as markers for mucin synthesis, glycosylation and sulfation, in the presence of 0–150 μM ebrotidine. 2. 2. The drug, while showing no discernible effect on the apomucin synthesis, evoked a dose-dependent increase in mucin glycosylation and sulfation, which at 100 μM ebrotidine, attained its maximum of 2.4 and 2.7-fold stimulation, respectively. 3. 3. The analysis of mucin secretory responses revealed that ebrotidine caused a concentration-dependent enhancement in Sulfomucin secretion which attained its maximum increase of 3.3-fold at 100–120 μM ebrotidine. Furthermore, the Sulfomucin elaborated in the presence of ebrotidine exhibited a higher content of a large molecular-weight mucus glycoprotein form, the assembly of which is intimately associated with the sulfation event. 4. 4. The results suggest that the ability of ebrotidine to enhance gastric Sulfomucin synthesis and secretion may play an important role in the gastroprotective mechanism of action of this agent.
-
Inhibition of Helicobacter pylori glycosulfatase activity towards human gastric Sulfomucin by a gastroprotective agent, sulglycotide.
General pharmacology, 1993Co-Authors: Varahabhotla L.n. Murty, A. Czajkowski, J. Piotrowski, Amalia Slomiany, Bronislaw L. SlomianyAbstract:Abstract 1. 1. A glycosulfatase activity towards human gastric Sulfomucin was identified in the extracellular material elaborated by Helicobacter pylori , a pathogen implicated in the etiology of gastric disease. 2. 2. The purified enzyme displayed an apparent molecular weight of 30 kDa, and exhibited maximum activity at pH 5.7 in the presence of 0.3% Triton X-100 and 100 mM CaCl 2 . 3. 3. The H. pylori glycosulfatase activity towards human gastric Sulfomucin was inhibited by a gastroprotective agent, sulglycotide. The inhibitory effect was proportional to the concentration of sulglycotide up to 20 μg/ml, at which a 98% decrease in mucin desulfation occurred. However, the drug lost the inhibitory effect following its chemical desulfation. 4. 4. The results demonstrate that sulglycotide is a potent inhibitor of H. pylori glycosulfatase and, hence, may be of value in the treatment of gastric disease associated with this bacterial infection.
Masae Tatematsu - One of the best experts on this subject based on the ideXlab platform.
-
Reciprocal control of colon-specific Sulfomucin and sialosyl-Tn antigen expression in human colorectal neoplasia
Virchows Archiv, 1997Co-Authors: T. Yamachika, Tatsuro Irimura, Hayao Nakanishi, Ken-ichi Inada, Kuniyoshi Kitoh, Tomoyuki Kato, Masae TatematsuAbstract:Histochemical reports claim that Sulfomucins decrease and sialylated mucins increase during colon carcinogenesis. We examined the expression of colon-specific Sulfomucins and sialosyl Tn antigen (STN) in normal small intestine, normal colorectal mucosa and colorectal tumours at different stages of progression immunohistochemically, using MAb 91.9H specific for colonic Sulfomucins and MAb TKH-2 for STN. No expression of Sulfomucins recognized by MAb 91.9H was found in normal small intestine, whereas STN staining was pronounced. The converse was the case in normal colorectal mucosa. Sulfomucins were still found in adenomas, but the amounts decreased with depth of invasion in cancers ( P
-
reciprocal control of colon specific Sulfomucin and sialosyl tn antigen expression in human colorectal neoplasia
Virchows Archiv, 1997Co-Authors: T. Yamachika, Tatsuro Irimura, Hayao Nakanishi, Ken-ichi Inada, Kuniyoshi Kitoh, Tomoyuki Kato, Masae TatematsuAbstract:Histochemical reports claim that Sulfomucins decrease and sialylated mucins increase during colon carcinogenesis. We examined the expression of colon-specific Sulfomucins and sialosyl Tn antigen (STN) in normal small intestine, normal colorectal mucosa and colorectal tumours at different stages of progression immunohistochemically, using MAb 91.9H specific for colonic Sulfomucins and MAb TKH-2 for STN. No expression of Sulfomucins recognized by MAb 91.9H was found in normal small intestine, whereas STN staining was pronounced. The converse was the case in normal colorectal mucosa. Sulfomucins were still found in adenomas, but the amounts decreased with depth of invasion in cancers (P<0.001). In contrast, no STN could be detected in benign lesions, but staining became increasingly evident with invasion (P<0.001). This reciprocal control of expression of colon-specific Sulfomucins and STN evident in tumour progression indicates that the mucous phenotype shifts from the colonic to the small intestinal type.
Amalia Slomiany - One of the best experts on this subject based on the ideXlab platform.
-
Association of salivary bacterial aggregating activity with Sulfomucin.
Biochemistry and molecular biology international, 1994Co-Authors: J. Piotrowski, Yotsumoto F, Amalia Slomiany, V. L.n. Murty, Czajkowski A, J. Majka, Bronislaw L. SlomianyAbstract:The requirements of human salivary mucins for aggregating potential towards the common cariogenic oral bacteria, S. mutans and S. sanguis, were investigated. Agglutination inhibition assays demonstrated that the aggregating capacity towards bacteria resides in the acidic mucin fraction. The inhibitory activity of the acidic mucin decreased only 2-4-fold following removal of sialic acid, whereas the desulfation caused a complete loss of the inhibitory potential against both bacteria. Furthermore, the aggregating capacity of mucin-derived sulfated oligosaccharide was found to be 16-fold higher than that of the sialic acid containing oligosaccharide. The results point towards the importance of salivary Sulfomucins as a predominant factor in the defense of oral cavity against cariogenic bacteria.
-
Inhibition of Helicobacter pylori colonization by an antiulcer agent, sulglycotide.
Biochemistry and molecular biology international, 1993Co-Authors: A. Czajkowski, J. Piotrowski, Yotsumoto F, Amalia Slomiany, Bronislaw L. SlomianyAbstract:Sulglycotide, a potent antiulcer agent derived from duodenal mucus glycopeptide through sulfation of the carbohydrate moieties, was evaluated with respect to its ability to interfere with H. pylori mucosal attachment. H. pylori cells were incubated with sulglycotide or human gastric mucin and then examined for their inhibitory capacity of H. pylori attachment to erythrocytes. Titration data revealed that the mucin inhibitory activity was confined to its Sulfomucin fraction, the titer of which was found to be 16-fold higher than that of intact mucin. The data with sulglycotide showed that the inhibitory titer of this agent against H. pylori attachment was at least 30-fold higher than that of the sulfated gastric mucin fraction. The results point towards the involvement of Sulfomucins in the protection of gastric mucosa from H. pylori colonization and demonstrate that sulglycotide, because of structural similarities, is ideally suited to augment the inherent mucosal defenses against this pathogen.
-
Nitecapone effect on the synthesis and secretion of gastric Sulfomucin
General pharmacology, 1993Co-Authors: Bronislaw L. Slomiany, Y.h. Liau, Amalia SlomianyAbstract:Abstract 1. 1. The effect of a new antiulcer agent, nitecapone, on the synthesis and secretion of Sulfomucin in gastric mucosa was investigated using mucosal segments incubated in the presence of [3H]proline, [3H]glucosamine and [35S]sulfate. 2. 2. The drug, while showing no discernible effect on the apomucin synthesis, evoked a dose-dependent increase in mucin glycosylation and sulfation, which at 225 μM nitecapone, attained its maximum of 1.8 and 2.2-fold stimulation, respectively. 3. 3. The analysis of mucin secretory responses revealed that nitecapone caused a concentration-dependent enhancement in Sulfomucin secretion attaining maximum increase of 1.5-fold at 150 μM nitecapone. 4. 4. The stimulatory effect of nitecapone on Sulfomucin secretion was accompanied by 1.4-fold increase in mucosal cAMP level, and showed sensitivity to protein kinase A inhibitors, thus pointing towards the involvement of protein kinase A in mediation of gastric Sulfomucin secretory responses to nitecapone. 5. 5. The ability of nitecapone to enhance Sulfomucin synthesis and secretion could be of importance to the gastroprotective action of this agent.
-
EFFECT OF EBROTIDINE ON THE SYNTHESIS AND SECRETION OF GASTRIC Sulfomucin
General pharmacology, 1993Co-Authors: Bronislaw L. Slomiany, Y.h. Liau, Amalia SlomianyAbstract:Abstract 1. 1. The effect of a new antiulcer agent, ebrotidine, on the synthesis and secretion of Sulfomucin in gastric mucosa was investigated. Rat gastric mucosal segments were incubated in DMEM containing [ 3 H]proline, [ 3 H]glucosamine and [ 35 S]Na 2 SO 4 as markers for mucin synthesis, glycosylation and sulfation, in the presence of 0–150 μM ebrotidine. 2. 2. The drug, while showing no discernible effect on the apomucin synthesis, evoked a dose-dependent increase in mucin glycosylation and sulfation, which at 100 μM ebrotidine, attained its maximum of 2.4 and 2.7-fold stimulation, respectively. 3. 3. The analysis of mucin secretory responses revealed that ebrotidine caused a concentration-dependent enhancement in Sulfomucin secretion which attained its maximum increase of 3.3-fold at 100–120 μM ebrotidine. Furthermore, the Sulfomucin elaborated in the presence of ebrotidine exhibited a higher content of a large molecular-weight mucus glycoprotein form, the assembly of which is intimately associated with the sulfation event. 4. 4. The results suggest that the ability of ebrotidine to enhance gastric Sulfomucin synthesis and secretion may play an important role in the gastroprotective mechanism of action of this agent.
-
Inhibition of Helicobacter pylori glycosulfatase activity towards human gastric Sulfomucin by a gastroprotective agent, sulglycotide.
General pharmacology, 1993Co-Authors: Varahabhotla L.n. Murty, A. Czajkowski, J. Piotrowski, Amalia Slomiany, Bronislaw L. SlomianyAbstract:Abstract 1. 1. A glycosulfatase activity towards human gastric Sulfomucin was identified in the extracellular material elaborated by Helicobacter pylori , a pathogen implicated in the etiology of gastric disease. 2. 2. The purified enzyme displayed an apparent molecular weight of 30 kDa, and exhibited maximum activity at pH 5.7 in the presence of 0.3% Triton X-100 and 100 mM CaCl 2 . 3. 3. The H. pylori glycosulfatase activity towards human gastric Sulfomucin was inhibited by a gastroprotective agent, sulglycotide. The inhibitory effect was proportional to the concentration of sulglycotide up to 20 μg/ml, at which a 98% decrease in mucin desulfation occurred. However, the drug lost the inhibitory effect following its chemical desulfation. 4. 4. The results demonstrate that sulglycotide is a potent inhibitor of H. pylori glycosulfatase and, hence, may be of value in the treatment of gastric disease associated with this bacterial infection.
T. Yamachika - One of the best experts on this subject based on the ideXlab platform.
-
Reciprocal control of colon-specific Sulfomucin and sialosyl-Tn antigen expression in human colorectal neoplasia
Virchows Archiv, 1997Co-Authors: T. Yamachika, Tatsuro Irimura, Hayao Nakanishi, Ken-ichi Inada, Kuniyoshi Kitoh, Tomoyuki Kato, Masae TatematsuAbstract:Histochemical reports claim that Sulfomucins decrease and sialylated mucins increase during colon carcinogenesis. We examined the expression of colon-specific Sulfomucins and sialosyl Tn antigen (STN) in normal small intestine, normal colorectal mucosa and colorectal tumours at different stages of progression immunohistochemically, using MAb 91.9H specific for colonic Sulfomucins and MAb TKH-2 for STN. No expression of Sulfomucins recognized by MAb 91.9H was found in normal small intestine, whereas STN staining was pronounced. The converse was the case in normal colorectal mucosa. Sulfomucins were still found in adenomas, but the amounts decreased with depth of invasion in cancers ( P
-
reciprocal control of colon specific Sulfomucin and sialosyl tn antigen expression in human colorectal neoplasia
Virchows Archiv, 1997Co-Authors: T. Yamachika, Tatsuro Irimura, Hayao Nakanishi, Ken-ichi Inada, Kuniyoshi Kitoh, Tomoyuki Kato, Masae TatematsuAbstract:Histochemical reports claim that Sulfomucins decrease and sialylated mucins increase during colon carcinogenesis. We examined the expression of colon-specific Sulfomucins and sialosyl Tn antigen (STN) in normal small intestine, normal colorectal mucosa and colorectal tumours at different stages of progression immunohistochemically, using MAb 91.9H specific for colonic Sulfomucins and MAb TKH-2 for STN. No expression of Sulfomucins recognized by MAb 91.9H was found in normal small intestine, whereas STN staining was pronounced. The converse was the case in normal colorectal mucosa. Sulfomucins were still found in adenomas, but the amounts decreased with depth of invasion in cancers (P<0.001). In contrast, no STN could be detected in benign lesions, but staining became increasingly evident with invasion (P<0.001). This reciprocal control of expression of colon-specific Sulfomucins and STN evident in tumour progression indicates that the mucous phenotype shifts from the colonic to the small intestinal type.
